Aveo’s Tivozanib Falls On Survival Data, Study Design Flaws
This article was originally published in The Pink Sheet Daily
Executive Summary
In a lopsided vote, FDA’s Oncologic Drugs Advisory Committee said the renal cell carcinoma drug has not been shown to have a favorable benefit/risk profile due to a negative trend in overall survival and flaws in the design and conduct of the sole pivotal trial.
You may also be interested in...
AVEO’s Fotivda: US FDA Concerns About Overall Survival Put To Rest By TIVO-3 Final Analysis
After repeatedly advising against tivozanib NDA submission on the basis of interim overall survival data that suggested a negative trend, agency ultimately concluded the final analysis did not suggest a detrimental effect in third-line renal cell carcinoma even though median overall survival was shorter than for the comparator agent, Bayer’s Nexavar.
Aveo Eyes Role For Tivozanib In US Kidney Cancer Market, Against The Odds
In the Phase III TIVO-3 study, tivozanib is associated with a trend toward adverse survival and trial has missing data issues.
US FDA Commissioner Califf Takes On Misinformation, Starting With ‘Rumor Control’
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.